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Abstract
OBJECTIVE: To investigate, in terms of Notch sig-
naling pathway, the effect on pancreatic cancer of
the extract of an anti-tumor prescription— Qingyi-
huaji formula (QYHJ) — from Traditional Chinese
Medicine (TCM).
METHODS: Nude mice were implanted subcutane-
ously with human pancreatic cancer cell line
SW1990 and then randomly divided into four
groups: Control, QYHJ extract, Gemcitabine, and
Combination of QYHJ extract and gemcitabine.
Treatments were given for 21 days and tumor
growth was evaluated simultaneously. Then, ex-
pression of Notch receptors (Notch-1, Notch-2,
Notch-3, and Notch-4) and their Jagged ligands
(Jagged-1 and Jagged-2) in dissected tumor tissue
were detected by real-time quantitative reverse
transcription-polymerase chain reaction and West-
ern blot. Finally, immunohistochemistry was per-
formed to detect CD133, a marker of pancreatic
cancer stem cells (CSCs), to evaluate the impact of
QYHJ extract on pancreatic CSCs.
RESULTS: QYHJ extract treatment effectively inhib-
ited the tumor growth in nude mice. The expres-
sion of both Notch-4 and Jagged-1 were de-
creased significantly in QYHJ treatment groups
(P < 0.05), while gemcitabine alone had no signifi-
cant effect in down-regulating Jagged-1 (P > 0.05).
No significant difference was observed in the ex-
pression of Notch-1, Notch-2, Notch-3, and Jag-
ged-2 between three treatment groups and con-
trol group (P > 0.05). Moreover, immunohisto-
chemical analysis showed that the number of
CD133 positive cells was significantly reduced by
QYHJ treatment (P < 0.05), and the combined
treatment was more effective than gemcitabine
alone (P < 0.05).
CONCLUSION: The role of the extract in pancreatic
cancer treatment was associated with down-regula-
tion of Notch-4 and Jagged-1 in Notch signaling
pathway. The extract could enhance the antitumor
activity of gemcitabine and was more effective
than gemcitabine in regulating Notch signaling
pathway to some extent.
© 2015 JTCM. All rights reserved.
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INTRODUCTION
Pancreatic cancer remains one of the leading lethal can-
cers across the world, with a 5-year survival rate less
than 6% .1 Because of its aggressive progression and
lack of symptoms during the early stage, only 20% of
patients are candidates of surgical resection after diag-
nosis.2 Currently available treatment options for ad-
vanced pancreatic cancer, such as gemcitabine, always
have strong side effects and can only slightly ameliorate
survival rate. Therefore, more effective agents are need-
ed urgently to control this deadly disease.
Qingyihuaji formula (QYHJ), consisting of traditional
Chinese herbs, has been used for integrative treatment
of human pancreatic cancer for many years. Our clini-
cal research indicates that QYHJ treatment combined
with conventional Western medicine has resulted in
prolonged survival time for patients with pancreatic
cancer.3,4 In addition, both clinical and animal studies
show a response advantage of QYHJ treatment in ad-
vanced pancreatic cancer with liver metastases.5,6 How-
ever, the underlying mechanism of its antitumor effect
on pancreatic cancer remains to be elucidated.
It is well reported that loss of normal regulation of cell
growth is the main cause of tumorigenesis, develop-
ment and metastasis. Notch signaling, an evolutionari-
ly conserved signaling pathway, plays an essential role
in regulating cell fate determination, differentiation,
proliferation, and apoptosis.7 So far, four Notch trans-
membrane receptors (Notch1-4) and five ligands (Jag-
ged-1, -2 and Delta-like 1, 3, 4) have been identified
in mammals.8 Activation of Notch signaling has previ-
ously been described in several human malignancies, in-
cluding pancreaticcancer.9,10 In the adult pancreas, lit-
tle-to-no expression of Notch signaling has been
found.11 However, over-expression of Notch receptors,
Notch ligands and Notch target genes have been ob-
served in pancreatic cancer.12,13 Moreover, Notch path-
way-related genes are detected in pancreatic cancer
stem cells (CSCs), which are thought to be responsible
for initiation, recurrence and metastasis of tumor.
Thus, Notch may have a part in pancreatic cancer ag-
gressiveness.14-17
The aim of the present study is to determine that QY-
HJ extract inhibited pancreatic cancer via Notch signal-
ing pathway. We examined the expression of four
Notch receptors (Notch1-4) and their Jagged ligands
(Jagged-1, -2) in the in vivo treatment of pancreatic tu-
mor xenografts in athymic nude mice. In addition, to
investigate the impact of QYHJ extract on pancreatic
CSCs, we detected the expression of CD133, a mean-
ingful cell surface marker of pancreatic CSCs.18,19
MATERIALS ANDMETHODS
Cell lines
Human pancreatic cancer cell line SW1990 was ob-
tained from the American Type Culture Collection
(ATCC, Manassas, VA, USA) and grown in complete
growth medium as recommended by the manufacturer.
The cultured cells were maintained in a humidified
5% CO2 atmosphere at 37℃.
QYHJ extract preparation and reagents
QYHJ is composed of Banzhilian (Herba Scutellariae
Barbatae) 30 g, Baihuasheshecao (Herba Hedyotdis)
15 g, Tiannanxing (Rhizoma Arisaematis Erubescentis)
15 g, Jiaogulan (Herba seu Radix Gynostemmatis Pen-
taphylli) 30 g and Doukou (Fructus Amomi Rotundus)
3 g. All herbs were purchased from Tianjiang Phar-
maceutical Co., (Jiangyin, China), and identified by
the Pharmaceutical Department of Fudan University
Shanghai Cancer Center (Shanghai, China).The daily
dosage for the nude mice is 36 g/kg,20,21 which was
calculated according to the following human-mouse
transfer formula: Db = Da × (Rb/Ra) × (Wb/Wa)2/3,
where D, R, and W represent dosage, shape coeffi-
cient, and body weight, respectively, and a and b rep-
resent human or mouse, respectively. The mixtures
were soaked in distilled water for 30 min and then
boiled in 10 volume of water (v/w) for 1 h and ex-
tracted twice. The supernatant was concentrated to a
final concentration of 3.6 g/mL (equivalent to dry
weight of raw materials). Gemcitabine (Eli Lilly, Indi-
anapolis, IN, USA) was stored at 4 ℃ and dissolved
in sterile PBS until use. Antibody against Notch-4
and antibody against Jagged-1 were purchased from
Santa Cruz Biotechnology (Dallas, TX, USA). Anti-
body against CD133 was purchased from eBioscience
(San Diego, CA, USA).
Animal models and treatment groups
Male BALB/c- nu/nu mice, five weeks old, weighing
16 g-20 g (Certificate of quality: No. SCXK [Hu]
2012-0002), were purchased from Animal Experimen-
tal Center, Zhejiang Chinese Medical University
(Hangzhou, China). Mice were acclimated for 7 days
and were raised in specific pathogen free conditions in
separate cages. Experiments reported in this study were
carried out in accordance with local guidelines for the
care of laboratory animals of Zhejiang Chinese Medi-
cal University, and were approved by the ethics com-
mittee for research on laboratory animal use of the in-
stitution.
SW1990 cells (5 × 106 cells in 0.2 mL) were injected
subcutaneously into the nape of each nude mouse.
At 24 h after cell inoculation, mice were randomly
divided into four groups (n = 6 in each group), us-
ing the table of random number: (a) Control (treated
with water, 10 mL/kg); (b) QYHJ extract alone (36 g/kg,
once daily p.o.); (c) Gemcitabine alone (25 mg/kg,22
twice weekly by i.p. injection); and (d) Combination
of QYHJ extract (36 g/kg, once daily p.o.) and gem-
citabine (25 mg/kg, twice weekly by i.p. injection).
Treatment was started the day after cell inoculation.
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Assessment of tumorigenicity in vivo
Tumor size was evaluated every 3 days by caliper mea-
surements using the following formula: tumor vol-
ume = (length × width2) / 2. After 21 days of treat-
ment, the experiment was halted, animals were sacri-
ficed and dissected tumors were weighed. Tumor tissue
was fixed in neutral-buffered formalin (10%), and em-
bedded in paraffin wax. The inhibition rate of tumor
growth was calculated using the following formula: tu-
mor growth inhibition rate (%) = (mean tumor weight
of the control mice－ mean tumor weight of the treat-
ed mice) / average tumor weight of the control mice ×
100%.
RNA extraction and real-time quantitative reverse
transcription-polymerase chain reaction (RT-PCR)
Total cellular RNA was extracted and pooled from
equal amounts of all snap-frozen xenograft tumors
from each treatment group using TRIzol® Reagent (TA-
KARA, Shiga, Japan) according to the manufacturer's
protocol. Aliquots of total cellular RNA (2 mg) were
subjected to first-strand cDNA synthesis using Super-
Script II reverse transcriptase (TAKARA, Shiga, Japan).
For real-time quantitative RT-PCR analysis, reactions
were performed using Hot Master Taq DNA Poly-
merase (TAKARA, Shiga, Japan) and SYBRGreen I
(BIO-RAD, Hercules, CA, USA). Reactions were per-
formed in triplicate using an iCycler iQ system
(BIO-RAD, Hercules, CA, USA). The target genes in-
cluded Notch-1, Notch-2, Notch-3, Notch-4, Jag-
ged-1and Jagged-2. GAPDH was included as the inter-
nal control. Specific primer sequences were designed
(Table 1).
Western blot analysis
A 100 mg sample of tumor tissue from each group was
dissected and immediately lysed in ice-cold RIPA lysis
buffer with protease inhibitor (0.5 mM phenylmethyl-
sulfonyl fluoride). Insoluble debris was removed by cen-
trifugation at top speed for 5 min. The supernatants
were stored at ﹣80 ℃. Equal amounts of supernatant
protein (200 µg) were denatured by boiling for 5 min
in SDS (sodium dodecyl sulfate) sample buffer, separat-
ed by 8% SDS-polyacrylate gel electrophoresis, and
transferred to a Nitrocellulose membrane for Western
blot analysis. Blot quantitative analysis was done with
Image studio software supported by the LI-COR (Lin-
coln, NE, USA). Protein levels were calculated relative
to β-actin.
Immunohistochemical analysis
Formalin-fixed, paraffin-embedded sections (4 μm)
were stained with anti-CD133 antibody (1∶150). Sam-
ples were analyzed by expert pathologists in a blinded
manner. Results were expressed as percentage of
CD133 positive cells. Five 400 × fields selected from
each tumor were examined in all treatment groups.
Statistical analysis
All the data were shown as Mean ± standard deviataion
( xˉ ± s) and analyzed using one-way analysis of vari-
ance plus least significant difference test with SPSS
16.0 (SPSS Inc., Chicago, IL, USA). P < 0.05 was sig-
nificant level.
RESULTS
Tumor growth inhibition
The results showed a drastic increase in tumor volume
in the control group as compared with other groups
(Figure 1). The mean tumor weight of the control mice
was (0.61 ± 0.16) g, and those of the mice treated with
Gene name
Notch-1 F
Notch-1 R
Notch-2 F
Notch-2 R
Notch-3 F
Notch-3 R
Notch-4 F
Notch-4 R
Jagged-1 F
Jagged-1 R
Jagged-2 F
Jagged-2 R
GAPDH F
GAPDH R
Primer sequence
5'-ATGCTGCTGTTGTGCTCCTGA-3'
5'-ATCCGTGATGTCCCGGTTG-3'
5'-TACCAGTGCAACTGCCAACCA-3'
5'-GATTGATGCCGTCCACACAGA-3'
5'-TCAGAATGTCCAGAGGCCAAGA-3'
5'-CACGGATATCAGCAGCAACCA-3'
5'-CAGGATCCACCTGTCACCAAGA-3'
5'-CGTGTAACCAGGCAGGCAGA-3'
5'-AAAGGCTTCACCGGCACCTA-3'
5'-CTCCCAGCCGTCACTACAGATACA-3'
5'-AGTTCCTGGATGGAAGACTGCAA-3'
5'-TGACCAGAGAGCAGGCAAGG-3'
5'-TGTGTCCGTCGTGGATCTGA-3'
5'-TTGCTGTTGAAGTCGCAGGAG-3'
Annealing temperature (℃)
60
60
60
60
60
60
60
Table 1 mRNA specific primer sequences and annealing temperatures
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QYHJ extract, gemcitabine, and combination of the ex-
tract and gemcitabine were (0.33 ± 0.13), (0.28 ±
0.17), and (0.20 ± 0.05) g, respectively (Figure 1). We
found that QYHJ extract alone significantly inhibited
the growth of the tumor within 46.04% tumor inhibi-
tion (P < 0.01 when compared to control). Gemcitabi-
ne alone had 53.30% tumor inhibition (P < 0.001
when compared to control; P > 0.05 when compared
to QYHJ extract group); and the combination group
was the most effective, the tumor mass was inhibited
by up to 66.67% (P < 0.001 when compared to con-
trol; P > 0.05 when compared to QYHJ extract alone
group or gemcitabine alone group).
Gene expression of Notch receptors and ligands in
tumor samples
To investigate whether QYHJ treatment regulated the
Notch signaling, we measured the mRNA expression
of Notch receptors consisting of Notch-1, Notch-2,
Notch-3, and Notch-4 as well as the ligands Jagged-1
and Jagged-2.The results demonstrated that when com-
pared to control, the expression of Notch-4 gene was
significantly decreased by QYHJ extract (P < 0.05),
gemcitabine (P < 0.05) and the combination treatment
(P < 0.05), and there was no big difference between
the three treatment groups (P > 0.05). Besides, QYHJ
extract and the combination group were more effective
in down-regulating the expression of Jagged-1gene
(P < 0.01), while gemcitabine alone had no significant
effect (P > 0.05). Moreover, the Notch-1, Notch-2,
Notch-3, and Jagged-2mRNA expression were also re-
duced by combined treatment of QYHJ extract and
gemcitabine, although there were no distinct changes
compared with the control group (P > 0.05) (Figure 2).
Protein expression of Notch-4 and Jagged-1 in tumor
samples
To further examine the protein expression of Notch-4
and Jagged-1, we performed Western blot, and quanti-
tative analysis was done with Image studio software. As
showed in Figure 3, the analysis revealed that the pro-
tein expression of Notch-4 was decreased significantly
in QYHJ extract, gemcitabine, and the combination
group compared with control (P < 0.001). And the
protein expression of Jagged-1 was also reduced effec-
tively in QYHJ extract and the combination group
(P < 0.001). QYHJ treatment seemed more effective,
although there was no significant difference compared
with other treatment groups (P > 0.05). These results
showed the same tendency as the real-time quantitative
RT-PCR analysis.
Effect of QYHJ extract on pancreatic CSCs
CD133 is specifically presented in pancreatic CSCs.
The results indicated that three treatment groups signif-
icantly reduced the CD133 expression as compared to
control group (P < 0.001), and the combined treat-
ment of QYHJ extract and gemcitabine was more effec-
tive than gemcitabine alone (P < 0.05) (Figure 4).
DISCUSSION
In this study, our results showed that the extract signifi-
cantly inhibited the tumor growth and increased the
antitumor activity of gemcitabine in nude mice. To fur-
ther explore its antitumor mechanism, we focused on
Notch signaling pathway, which is involved in tumor
initiation and tumor maintenance in pancreatic cancer.
In previous studies, Notch receptors and their Jagged li-
gands were significantly over-expressed in pancreatic
cancer cells,12,13 and down-regulation of molecules such
as Notch-1 or Notch-2 contributes to cell growth inhi-
bition and apoptosis.23,24 These findings suggest that
the down-regulation of Notch pathway could be a nov-
el therapeutic approach for the treatment of pancreatic
cancer. To confirm the impact of QYHJ extract, we in-
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Figure 1 Effect of QYHJ extract on pancreatic tumor growth
A: time-dependent inhibition of growth of pancreatic tumors; B: mean tumor weight. Control group were treated with water,
10 mL/kg. QYHJ group were treated with QYHJ extract 36 g/kg, once daily p.o. Gemcitabine group were treated with Gemcitabine
25 mg/kg twice weekly by i.p. injection. Combination group were treated with QYHJ 36 g/kg, once daily p.o. and gemcitabine
25 mg/kg, twice weekly by i.p. injection. QYHJ: Qingyihuaji formula extract; Gem: gemcitabine. aP < 0.01, bP < 0.001, compared
with the control group.
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vestigated expression of Notch related molecules in this
experiment, and found that QYHJ extract down-regu-
lated the expression of Notch-4 and Jagged-1 in both
mRNA and protein levels, which was more effective
than gemcitabine treatment, indicating that it might in-
hibit the growth of pancreatic cancer by targeting
Notch-4 and Jagged-1.
In addition, we focused on a renewed perspective on
tumorigenesis as a process governed by a distinct popu-
lation of cells, termed cancer stem cells (CSCs). Emerg-
ing data have suggested that only a few cells within the
malignant tumor, the CSCs, are responsible for tumor
initiation and propagation.25,26 The CSCs also plays a vi-
tal role in predicting prognosis of cancer patients, in-
cluding pancreatic cancer patients. Patients detected at
high levels of CSCs lead to poor prognosis,27,28 and tar-
geting CSCs results in prolonged survival.29,30
Several cellular signaling pathways have been identified
that regulate the self-renewal of CSCs and may serve as
targets against CSCs, including the Notch pathway.14,15
It was reported that pancreatic CSCs contain higher
levels of expression for Notch molecules than non-pan-
creatic CSCs, and the down-regulation of Notch signal-
ing was associated with decreased invasive behavior of
pancreatic CSCs.16,17 Therefore, eradication of CSCs by
Notch-targeted therapy may be useful for complete
eradication of tumors, which will certainly improve the
overall survival of patients diagnosed with pancreatic
cancer.
As mentioned above, CD133 positive cells are defined
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Figure 2 Real-time quantitative RT-PCR analyses on expression of Notch-1, Notch-2, Notch-3, Notch-4, Jagged-1and Jagged-2
A: relative mRNA expression of Notch-1; B: relative mRNA expression of Notch-2; C: relative mRNA expression of Notch-3; D: rela-
tive mRNA expression of Notch-4; E: relative mRNA expression of Jagged-1; F: relative mRNA expression of Jagged-2. Control
group were treated with water, 10 mL/kg. QYHJ group were treated with QYHJ extract 36 g/kg, once daily p.o. Gemcitabine group
were treated with Gemcitabine 25 mg/kg twice weekly by i.p. injection. Combination group were treated with QYHJ 36 g/kg,
once daily p.o. and gemcitabine 25 mg/kg, twice weekly by i.p. injection. RT-PCR: reverse transcription-polymerase chain reaction;
QYHJ: Qingyihuaji formula extract; Gem: gemcitabine. aP < 0.05, bP < 0.01, compared with the control group.
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as pancreatic CSCs, our data showed that the extract
significantly reduced the number of CD133 positive
cells, and it also enhanced the effect when combined
with gemcitabine. This result indicated that QYHJ
treatment may prolong the survival time of patients by
decreasing the levels of pancreatic CSCs, which was in
accordance with our clinical observation. And
down-regulating CSCs related Notch signaling path-
way might be its potential mechanism. However, this
was only a preliminary study, leaving more space for
further research.
In conclusion, QYHJ extract displayed its significant ef-
fect against the growth of pancreatic cancer probably
by down-regulating pancreatic CSCs and related
Notch signaling pathway. It is considered that Notch-4
and Jagged-1 might be potential targets for QYHJ
treatment. The extract could also enhance the antitu-
mor activity in regulating Notch signaling pathway.
This study may help better understand the clinical ef-
fectiveness of QYHJ extract and it could be an alterna-
tive for pancreatic cancer patients.
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